Who are the Leading Companies in the microRNA Market?
- Thermo Fisher Scientific, Inc.
- DiamiR Biosciences
- New England Biolabs
- NanoString Technologies, Inc.
- Sanofi
- miRecule
- Alnylam
- BioGenex
- Merck KGaA
- LGC Limited
- Takara Bio, Inc.
- Horizon Discovery Group plc.
- QIAGEN
- GeneCopoeia, Inc.
Market Growth
The global microRNA market was estimated at US$ 1.61 billion in 2023 and is projected to grow to US$ 6.11 billion by 2034, rising at a compound annual growth rate (CAGR) of 12.89% from 2024 to 2034. The increasing prevalence of chronic conditions is driving the market’s growth.
Download Free Sample of microRNA Market Now and Get the Complete Report Easily at: https://www.towardshealthcare.com/download-sample/5211
Top Companies’ Info
- Bio-Techne Corporation is an American life sciences company that develops, manufactures, and sells reagents, instruments, and services. The company offers miRNAscope Assay Red for detecting smRNA. The fourth-quarter 2024 revenue was $306.1 million, and the full-year 2024 revenue was $1.2 billion, an organic increase of 1%.
- Takara Bio, Inc. is a biotechnology company that provides a wide range of life science reagents. The company offers microRNA first-strand synthesis and miRNA quantitation kits. The FY2025 revenue was 45,039 million yen, compared to 43,505 million yen in 2024.
The Biotechnology & Pharmaceutical Companies Segment Dominated
By end-use, the biotechnology & pharmaceutical companies segment dominated the microRNA market in 2023. The main function of microRNA is in therapeutics and various sequencing-associated activities. Both biotechnology and pharmaceutical companies are highly invested in the development of new therapeutics and understanding the function of genes. As the population grows, unhealthy lifestyles and environmental conditions contribute to chronic conditions, pharma, and biotech companies are conducting clinical trials and research studies. Companies are heavily investing and collaborating with other companies and government institutions to come up with better solutions.
For instance,
- In March 2023, The University of Leipzig in Germany and the RNA delivery and therapeutics business SiSaf Ltd. will work together to create tailored micro-interfering RNAs (miRNA) for the treatment of cancer, with a primary focus on pancreatic cancer. In the lab of Achim Aigner, SiSaf will create formulations of miRNA Bio-Courier that will be tested in pancreatic cancer models. As per the agreement, SiSaf is the only party that has the ability to purchase a worldwide license for a patent held by the institution.
Regional Companies Insights
Asia Pacific
- In 2022, MiRXES, a Singaporean company, announced that it would collaborate with the National Heart Centre and National University Heart Centres in Singapore to manage pulmonary hypertension. Thanks to the collaboration, the first multi-center study employing early detection microRNA biomarkers in Southeast Asia has begun. The institute wants to use microRNA biomarkers to identify pulmonary hypertension at an early stage.
Recent Developments in the microRNA Market
- In July 2024, adult mice with a particular kind of hereditary hearing loss have had their hearing restored by researchers using gene editing. They demonstrated that the animal’s ability to hear was restored by blocking a defective copy of a gene known as a microRNA (miRNA). The method used by a National Institutes of Health (NIH))-supported research team, published in Science Translational Medicine, may potentially result in hereditary hearing loss remedies for humans.
- In February 2024, the FDA in the United States gave the go-ahead for ARTHEx Biotech S.L. to begin the Phase I-IIa ArthemiRTM study of ATX-01 for the treatment of Myotonic Dystrophy Type 1 (DM1). ARTHEx Biotech S.L. is a clinical-stage biotechnology company focused on developing novel medicines through the modulation of microRNAs.
- In September 2023, Researchers at Purdue University created a novel cancer treatment that targets tumors by deceiving cancer cells into ingesting a little piece of microRNA that normally prevents cell proliferation. According to a paper published in Oncogene on Monday, September 4, during a 21-day trial, tumors treated with the novel therapy did not grow in size, but tumors that were left untreated tripled in size during the same timeframe.
Access our exclusive, data-rich dashboard dedicated to the biotechnology sector – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
Checkout microRNA Market Report Now at: https://www.towardshealthcare.com/checkout/5211
Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Powering Healthcare Leaders with Real-Time Insights: https://www.towardshealthcare.com/healthcare-intelligence-platform
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
About the Author
